Characterization of the tumor immune microenvironment (TME) in early stage HR-positive HER2-positive breast cancer

被引：0
|
作者：
Fenn, Kathleen M. [1 ]
Marks, Douglas K. [2 ]
Vanguri, Rami [1 ]
Boboila, Shuobo [1 ]
Guo, Hua [1 ]
Hibshoosh, Hanina [1 ]
Kalinsky, Kevin [1 ]
Connolly, Eileen [1 ]
机构：
[1] Columbia Univ, Irving Med Ctr, New York, NY USA
[2] NYU, New York, NY USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS19-P6-10-25
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-10-25
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Everolimus Approved for HR-Positive Breast Cancer
    不详
    CANCER DISCOVERY, 2012, 2 (09) : 756 - 756
  • [42] Clinical relevance of clinical treatment score post-5 years (CTS5) in HR-positive, HER2-positive breast cancer
    Soong June Bae
    Sohyun Moon
    Yoonwon Kook
    Seung Ho Baek
    Minji Lee
    Jee Hung Kim
    Sung Gwe Ahn
    Joon Jeong
    npj Breast Cancer, 11 (1)
  • [43] Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer
    Hanne Vos
    Kathleen Lambein
    François Richard
    Bram Mariën
    Ines Nevelsteen
    Kevin Punie
    Hans Wildiers
    Lieze Berben
    Annouschka Laenen
    Giuseppe Floris
    Christine Desmedt
    Ann Smeets
    npj Breast Cancer, 7
  • [44] Characterization of the tumor microenvironment in patients with hormone receptor positive, HER2 negative early breast cancer
    Kearney, Matthew Ryan
    Vanguri, Rami
    Wang, Qi
    Fenn, Kathleen
    Guo, Hua
    Marks, Douglas
    Hibshoosh, Hanina
    Kalinsky, Kevin M.
    Connolly, Eileen
    CANCER RESEARCH, 2022, 82 (04)
  • [45] Optimal neoadjuvant treatment and prognostic factors in patients with HR-positive/HER2-positive early or locally advanced breast cancer: A national real-world study in China
    Liu, Zhenzhen
    Zhu, Jiujun
    Wang, Chengzheng
    Lu, Zhenduo
    Chen, Xiuchun
    Li, Lianfang
    Sun, Xianfu
    Zhang, Chongjian
    Qiao, Jianghua
    Yan, Min
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [46] Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer
    Vos, Hanne
    Lambein, Kathleen
    Richard, Francois
    Marien, Bram
    Nevelsteen, Ines
    Punie, Kevin
    Wildiers, Hans
    Berben, Lieze
    Laenen, Annouschka
    Floris, Giuseppe
    Desmedt, Christine
    Smeets, Ann
    NPJ BREAST CANCER, 2021, 7 (01)
  • [47] Neratinib as extended adjuvant treatment of HER2-positive/HR-positive early breast cancer patients in Germany, Austria and Switzerland: interim results of the prospective, observational ELEANOR study
    Harbeck, Nadia
    Wrobel, Denise
    Zaiss, Matthias
    Terhaag, Juergen
    Guth, Dagmar
    Distelrath, Andrea
    Zahn, Mark-Oliver
    Wuerstlein, Rachel
    Lorenz, Andreas
    Bartsch, Rupert
    Breitenstein, Urs
    Schwitter, Michael
    Balic, Marija
    Jackisch, Christian
    Mueller, Volkmar
    Rinnerthaler, Gabriel
    Schmidt, Marcus
    Zaman, Khalil
    Schinkoethe, Timo
    Resch, Anna
    Valenti, Roberta
    Lueftner, Diana
    BREAST CARE, 2024, 19 (01) : 1 - 9
  • [48] The tumor immune microenvironment remodeling and response to HER2-targeted therapy in HER2-positive advanced gastric cancer
    Jiang, Lei
    Zhao, Xingwang
    Li, Yilin
    Hu, Yajie
    Sun, Yu
    Liu, Shengde
    Zhang, Zizhen
    Li, Yanyan
    Feng, Xujiao
    Yuan, Jiajia
    Li, Jian
    Zhang, Xiaotian
    Chen, Yang
    Shen, Lin
    IUBMB LIFE, 2024, 76 (07) : 420 - 436
  • [49] Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer
    Esther S. Kim
    Lesley J. Scott
    Targeted Oncology, 2017, 12 : 373 - 383
  • [50] Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer
    Kim, Esther S.
    Scott, Lesley J.
    TARGETED ONCOLOGY, 2017, 12 (03) : 373 - 383
12345